These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12678250)

  • 1. Advanced process monitoring: the ultimate alternative.
    Neeleman R; Beuvery C
    Dev Biol (Basel); 2002; 111():273-82. PubMed ID: 12678250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three Rs potential in the development and quality control of immunobiologicals.
    Halder M
    ALTEX; 2001; 18 Suppl 1():13-47. PubMed ID: 11854853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three Rs potential in the development and quality control of pharmaceuticals.
    Hartung T
    ALTEX; 2001; 18 Suppl 1():3-13. PubMed ID: 11854852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving the cellular pertussis vaccine: increased potency and consistency.
    Thalen M; van der Ark A; van den Ijssel J; van Straaten I; Jansen D; Beuvery C; Martens D; Tramper J
    Vaccine; 2008 Jan; 26(5):653-63. PubMed ID: 18155325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAT for vaccines: the first stage of PAT implementation for development of a well-defined whole-cell vaccine against whooping cough disease.
    Streefland M; van de Waterbeemd B; Happé H; van der Pol LA; Beuvery EC; Tramper J; Martens DE
    Vaccine; 2007 Apr; 25(16):2994-3000. PubMed ID: 17313999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards eliminating the use of animals for regulatory required vaccine quality control.
    Hendriksen CF
    ALTEX; 2006; 23(3):187-90. PubMed ID: 17086348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consistency as tool to support in vitro batch potency testing in GMP production.
    Stirling C
    Dev Biol (Basel); 2012; 134():115-8. PubMed ID: 22888603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 4R concept for the safety testing of immunobiologicals.
    Cussler K
    Dev Biol Stand; 1999; 101():121-6. PubMed ID: 10566784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ensuring quality of in vitro alternative test methods: Current practice.
    Rispin A; Stitzel K; Harbell J; Klausner M
    Regul Toxicol Pharmacol; 2006 Jul; 45(2):97-103. PubMed ID: 16644076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward Higher QA: From Parametric Release of Sterile Parenteral Products to PAT for Other Pharmaceutical Dosage Forms.
    Hock SC; Constance NX; Wah CL
    PDA J Pharm Sci Technol; 2012; 66(4):371-91. PubMed ID: 22767885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A practical approach for exploration and modeling of the design space of a bacterial vaccine cultivation process.
    Streefland M; Van Herpen PF; Van de Waterbeemd B; Van der Pol LA; Beuvery EC; Tramper J; Martens DE; Toft M
    Biotechnol Bioeng; 2009 Oct; 104(3):492-504. PubMed ID: 19598176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory processes and three Rs alternatives.
    Milstien J
    Dev Biol (Basel); 2002; 111():15-9. PubMed ID: 12678220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement.
    Hendriksen CF
    Expert Rev Vaccines; 2009 Mar; 8(3):313-22. PubMed ID: 19249973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality control of biologicals produced by recombinant DNA techniques. WHO consultation.
    WHO Consultation
    Bull World Health Organ; 1983; 61(6):897-911. PubMed ID: 6609009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Batch potency testing of inactivated erysipelas vaccines by ELISA--development, validation and implementation.
    Rosskopf-Streicher U; Johannes S; Gyra H; Beckmann R; Cussler K
    Dev Biol (Basel); 2002; 111():153-8. PubMed ID: 12678235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-processing strategies for biologicals API manufacturing processes.
    Opitz U
    Dev Biol (Basel); 2003; 113():101-4; discussion 115-6. PubMed ID: 14620858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The development and approval of alternative methods to bioassays used for quality assurance, a challenge for the pharmaceutical industry and the authorities].
    Miethe G; Sponer G
    ALTEX; 2002; 19(3):115-21. PubMed ID: 12165813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of recombinant DNA produced pharmaceuticals by a combination of process validation and final product specifications.
    Jones AJ; O'Connor JV
    Dev Biol Stand; 1985; 59():175-80. PubMed ID: 4007276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality control and analytical techniques for biopharmaceuticals.
    Robinson CJ; Jones C
    Bioanalysis; 2011 Jan; 3(1):81-95. PubMed ID: 21175369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The control of biological medicinal products produced by recombinant DNA technology.
    Griffiths E
    Dev Biol Stand; 1985; 59():155-9. PubMed ID: 4007273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.